Taiwan National Health Insurance Administration of the Ministry of Health and Welfare Approves Vemlidy(R) (tenofovir alafenamide) for Reimbursement

TAIPEI, Taiwan, April 29, 2019 /PRNewswire/ -- Gilead Sciences, Inc. today announced that with effect from 1 May 2019, Vemlidy (tenofovir alafenamide, TAF) 25 mg, a once-daily treatment for chronic hepatitis B in adults with compensated liver disease will be made available to patients via ...

from PR Newswire: https://prn.to/2GSkMhI